Quick Answer
Anebulo Pharmaceuticals, Inc. reported Diluted EPS of $0.25 per share (loss) for fiscal year 2025.
Anebulo Pharmaceuticals, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.25 | +21.9% |
| 2024 | -$0.32 | +31.9% |
| 2023 | -$0.47 | -262.1% |
| 2022 | $0.29 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$0.05 | +44.4% | +0.0% |
| September 30, 2025 | -$0.05 | +37.5% | -25.0% |
| March 31, 2025 | -$0.04 | +33.3% | +55.6% |
| December 31, 2024 | -$0.09 | +18.2% | -12.5% |
| September 30, 2024 | -$0.08 | +20.0% | -33.3% |
| March 31, 2024 | -$0.06 | +45.5% | +45.5% |
| December 31, 2023 | -$0.11 | +26.7% | -10.0% |
| September 30, 2023 | -$0.10 | +9.1% | +9.1% |
- Anebulo Pharmaceuticals, Inc. showed an increase of +21.9% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Anebulo Pharmaceuticals, Inc.’s diluted eps has declined by 186.2% (from $0.29 per share to $0.25 per share (loss)).
- The most recent figure is from Anebulo Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: